Comparison of left and right ventricular pulsed and tissue Doppler myocardial performance index values using Z-score in newborns with hypoxic-ischemic encephalopathy

Alp, Hayrullah; Karaaslan, Sevim; Baysal, Tamer; Oran, Bülent; Örs, Rahmi

doi:10.5152/akd.2011.194

Cited by 2 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neonatal hypoxic‐ischemic encephalopathy (HIE) is a clinically defined neurological condition with deficiency of oxygen, while the HIE often associated with cardiac dysfunction in term infants (Liu X, et al, 2011). And The degree of cardiac response in neonates with HIE is associated with the severity of hypoxia (Alp H, et al, 2011). Correlational research reported for the first time that acute cerebral ischemia significantly increased left ventricular end diastolic pressure (LVEDP), but decreased left ventricular systolic pressure (LVSP), which indicate that acute cerebral ischemia may specifically disturb cardiac function and calcium homeostasis, subsequently leading to Ca 2+ overload and myocardial dysfunction (Sun L, et al, 2010).…”

Section: Bcl‐2 Cerebral Ischemia and Myocardial Ischemiamentioning

confidence: 99%

Research progress of IGF‐1 and cerebral ischemia

Zhou

et al. 2021

Ibrain

View full text Add to dashboard Cite

Cerebral ischemic disease is a group of diseases that cause insufficient blood supply to the cerebrum, cerebellum or brain stem for different reasons, resulting in corresponding nervous system symptoms. Cardiovascular disease is the leading cause of death in the world. Among them, the death caused by cerebral ischemia accounts for the vast majority, and it is one of the fatal diseases in the middle‐aged and elderly at present. Epidemiologic studies have projected increasing mortality due to cardiovascular disease worldwide (about 23.3 million people by 2030) because of the aging population. However, related studies have shown that insulin‐like growth factor I (IGF‐1) is a multifunctional cell proliferation regulator. It plays an important role in cerebral ischemia. It is effective in promoting cell differentiation, proliferation and individual development. Studies have shown that IGF‐1 signaling pathway is a key pathway controlling cell growth and survival. There may be five mechanisms in cerebral ischemia: prevention of intracellular calcium overload, inhibition of the upregulation of nNOS, IGF‐1upregulations activating HIF‐1α, regulation of Bcl‐2 to resist apoptosis, and enhancement of vascular endothelial function. Three critical nodes in the IGF‐1 signaling pathway have been described in cardiomyocytes: protein kinase Akt/mammalian target of rapamycin (mTOR), Ras/Raf/extracellular signal‐regulated kinase (ERK), and phospholipase C (PLC)/inositol 1,4,5‐triphosphate (InsP3)/Ca2+. IGF‐1 plays an important role in cerebral ischemia and myocardial ischemia, mainly by activating downstream of IGF‐1, controlling cell death and differentiation or transcription work, improving the function of heart muscle cells, reducing the myocardial cell apoptosis induced by myocardial infarction, regulating endogenous protection and restoration of cerebral ischemia injury, thus protecting cerebral and myocardial injury. Related studies have shown that bcl‐2 exerts great influence on both cerebral ischemia and myocardial ischemia. Therefore, the relevant pathways and targets of cerebral ischemia and myocardial ischemia and the role of IGF‐1 in protecting the heart are reviewed in this paper.

show abstract

Section: Bcl‐2 Cerebral Ischemia and Myocardial Ischemiamentioning

confidence: 99%

Research progress of IGF‐1 and cerebral ischemia

Zhou

et al. 2021

Ibrain

View full text Add to dashboard Cite

show abstract

Coronary sinus dilatation is a sign of impaired right ventricular function in patients with heart failure

Cakici

Doğan²,

Çetın³

et al. 2015

Anatol J Cardiol

View full text Add to dashboard Cite

Objective:The coronary sinus (CS) has been largely ignored by physicians due to a lack of adequate data about the importance of CS enlargement in patients with heart failure (HF). We aimed to assess whether CS dilatation develops in patients with HF and to demonstrate its relation with global myocardial function of the right ventricle (RV).Methods:In this cross-sectional study, 45 healthy subjects and 95 HF patients exhibiting left ventricular systolic dysfunction on echocardiographic examination (EF <45%) secondary to ischemic (n=56) or idiopathic dilated cardiomyopathy (DCM) (n=39) were enrolled. Patients with severe renal dysfunction and/or valve disease were excluded. CS was measured by echocardiography from the posterior atrioventricular groove in the apical four-chamber view. The RV myocardial performance index (MPI), which reflects both systolic and diastolic function of the ventricle, was detected using tissue Doppler imaging, and patients with an RV MPI >0.55 were defined as having impaired RV myocardial function. ANOVA, Kruskal-Wallis, Pearson’s correlation, and multivariate logistic regression analyses were used for the statistical analysis.Results:The CS and RV MPI values were significantly greater both in patients with ischemic and idiopathic DCM than in controls (8.79±1.7 mm and 8.33±2.1 mm vs. 5.74±0.6 mm, and 0.64±0.07 and 0.62±0.08 vs. 0.43±0.02; p<0.001 for both, respectively). For the prediction of HF patients with impaired RV function, the cut-off value for the diameter of the CS was 7.35 mm, with a sensitivity of 83% and a specificity of 79%.Conclusion:The CS diameter can be used as a novel echocardiographic marker that provides information about impaired RV function in patients with HF.

show abstract

Comparison of left and right ventricular pulsed and tissue Doppler myocardial performance index values using Z-score in newborns with hypoxic-ischemic encephalopathy

Cited by 2 publications

References 9 publications

Research progress of IGF‐1 and cerebral ischemia

Research progress of IGF‐1 and cerebral ischemia

Coronary sinus dilatation is a sign of impaired right ventricular function in patients with heart failure

Contact Info

Product

Resources

About